Simultaneous treatment of moderate-to-severe horizontal frontalis lines, glabellar lines, and lateral canthal lines with onabotulinumtoxinA, from the subject’s perspective: Patient-reported satisfaction and impact outcomes from a phase 3 double-blind study (Journal of the American Academy of Dermatology, 2018)